Pirlindole

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pirlindole
Pirlindole structure.svg
Clinical data
Trade namesPirazidol
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20–30%
Protein binding95%
Metabolismhepatic
Onset of action2 to 8 hours
Elimination half-life2.1 hours [1]
Excretionurine (50–70%), feces (25–45%)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC15H18N2
Molar mass226.32 g/mol
3D model (JSmol)

Pirlindole (Lifril, Pyrazidol) is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is used in Russia as an antidepressant.[2]:337 It is structurally and pharmacologically related to metralindole.

See also[edit]

References[edit]

  1. ^ Pöldinger, W. (1985). Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline. In Psychiatry the State of the Art (pp. 283-289). Springer, Boston, MA. ISBN 978-1-4613-2363-1 [1]
  2. ^ Medvedev AE, et al. The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding. Chapter 36 in MAO - The Mother of all Amine Oxidases (Journal of Neural Transmission. Supplementa). Eds Finberg JPM, Youdim MBH, Riederer P, Tipton KF. Special edition of Journal of Neural Transmission, Suppl. 52 1st ed. 1998 ISBN 978-3211830376